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using corticosteroids (p =  0.0005, p < 0.0067 res ectively). 
Despite earlier reports, blood concentrations of YKL-40, 
Fetuin-a and haptoglobin were not predictive for response. 
In addition, serum peptide profiles, determined by MALDI-
TOF mass spectroscopy, were not predictive as well. In 
conclusion, further biomarker discovery studies are needed 
to predict treatment outcome for patients with GBM in the 
near future.
Keywords Glioblastoma multiforme · Biomarker · 
Proteomics · First-line treatment
Introduction
Despite intensive treatment, general prognosis of patients 
with a glioblastoma multiforme (GBM) remains dismal with a 
median survival rate of approximately 15 months and a 2yea  
survival rate of around 25 % [1]. Current standard first-line 
treatment takes about 9 months t  be completed and consists 
of surgical debulking, followed by radiotherapy with concomi-
tant and adjuvant temozolomide [1]. This treatment regimen 
induces a significant burden due to its toxicity (e.g. bone mar-
row toxicity and fatigue), and takes a relatively long period of 
time. Upfront selection of GBM patients who will have no ben-
efit from this multimodality treatment, is currently not possible. 
The methylation of the MGMT-gene promotor was shown to 
be a prognostic and a relatively weak predictive biomarker 
for the response to temozolomide monotherapy, and therefore 
clinically used only for older frail patients, when tolerability 
of the combination treatment is questionable [2]. IDH1 mu a-
tions were pos ulated as a potential predictive biomarker, but 
its value has to be confirmed before implementation in daily 
p actice [2, 3]. Assessments of both these markers and other 
potential genetic biomarkers require tumor tissues, which is 
Abstract Surgery followed by chemoradiation and adju-
vant chemotherapy is standard of care for patien  with a 
glioblastoma (GBM). Due to its limited benefit, an upfront 
method to predict dismal outcome woul  prev nt unneces-
sary toxic treatment. We searched for a predictive blood 
derived biomarker in a cohort of 55 patien s with GBM. 
Increasing age (HR 1.03, 95 % CI 1.01–1.06), and post-
operative tumor residue (HR 1.07, 95 % CI 1.02–1.15) 
were independently associated with unfavourable progres-
sion free survival (PFS) in these patients. Cort costeroid 
use before start of chemoradiat n wa  strongly predictive 
for outcome (HR 3.26, 95 % CI 1.67–6.3 ) with a mean 
PFS and OS in patients using corticosteroids of 7.3 and 
14.6 months, versus 16.1 and 21.6 months in patients not 
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Postoperative tumor volume or tumor residue was calcu-
lated by using iPlan Net3.0.0 software (BrainLAB AG, Ger-
many) by subtracting T1 spontaneous hyperintense signal 
on MRI (due to blood degradation products) in the resection 
cavity from the contrast enhancing residue.
Disease progression was assessed using the Macdonald 
criteria [12].
Serum sample handling
Venous blood was collected in 7 mL tubes (Cat #367615,BD, 
Franklin Lakes, NJ) and allowed to clot for 30 min-1 h at RT. 
The 1 h at RT is an optimal time window that is needed to 
allow endogenous cancer specific proteases to cleave abun-
dant blood proteins released by the clotting process, described 
by Villanueva et al. [5]. Blood was centrifuged at 1500g for 
10 min at RT. Serum aliquots of 300  µL were taken, frozen and 
stored in polypropylene Eppendorf tubes at −80 °C until fur-
ther use. All samples underwent one freeze thaw cycle before 
measurement. To keep pre-analytical variables as constant as 
possible in order to maintain the quality of the samples, a stan-
dardized, reproducible workflow has been implemented in our 
translational proteomic facility as described before [14].
Sample spotting and MALDI-TOF mass spectrometry
Peptide capture and measurement was performed as 
described before [13]. MALDI-TOF-MS was performed 
in reflectron positive mode on the 4800 MALDI-TOF/TOF 
mass spectrometer (Applied Biosystems) with 5000 shots 
per spectrum. The instrument was calibrated using a cali-
brant peptide mixture. Linear mode spectra were acquired 
from m/z800 through 4000.
Serum protein measurements
Protein concentrations of previously published candidate 
biomarkers were measured by ELISA. YKL-40 (Sunred 
Biological Technology Co) and Fetuin-A (α2-Heremans-
Schmid glycoprotein, R&D systems) measurements were 
performed according to manufacturer’s instructions. Hapto-
globin concentrations were determined by standard immu-
nonefolometry, using a immage 800 immunochemistry 
system (Beckman Coulter Inc.). Thrombocyte counts were 
measured on a CD4000 impedance hematology analyzer.
Statistical analysis
Treatment outcome was determined by calculating time 
between surgery and disease progression [progression free 
survival (PFS) or death (OS)]. Kaplan–Meier graphs, his-
tograms of treatment response and non-linear fitting of 
Gaussian distributions were performed in Graphpad prism 
not available at any given time during the treatment or fol-
low up. Tumor tissue from patients with GBM is more diffi-
cult to obtain than a venous puncture. With a blood derived 
tumor marker consecutive follow-up valuations of treatment 
response would be possible in order to pr vent unnec ss ry 
treatment or treatment related toxicity. The availability of a 
blood biomarker, obtained th ough an easy venous puncture, 
predicting response to treatment in an early stage, would be an 
important advantage for GBM patients. It is k own that pro-
teolytic cascades within the tumor microenvironment may gen-
erate disease specific proteins and peptide fragments that are 
being released in blood of patients. Also proteases themselves 
are shed by tumors, inducing modulations of blood pro eins 
while in the circulation as well as after bl od collection ex vivo 
[4, 5]. Therefore serum and plasma have been s udied as  bio-
marker source.
In previous studies it was found that the YKL-40 concentra-
tion in serum and the YKL-40 expression in tumors is elevated 
[6, 7]. Comparative genomic hybridization studies and gen  
expression array analysis of GBM tumor tissue revealed tha  
YKL-40 was associated with chromo ome-10 l ss and poor 
clinical outcome [8]. Fetuin-A is one of th m st abundant 
plasma glycoproteins and was also identified as a potential bio-
marker for patients with a high grade glioma. The serum Fetuin-
A concentration, before start of treatment, w s associated with 
survival in patients with GBM, especially when combined with 
age and Karnofsky performanc  score (KPS) [9]. Similarly, 
haptoglobin was found to be significantly up-regulated in serum 
of GBM patients and may play a ole in tumor angiogenesis 
and proliferation of cancer cell  [10]. A correlation between 
decreased platelet counts during conc rrent radiotherapy nd 
temozolomide treatment and a positive effect on overall sur-
vival (OS) has been described in patients with a GBM [11].
In this exploratory study, we investigated whether serum 
peptides as well as serum concent a io s of haptoglobin, 
thrombocytes, YKL-40 and Fetuin-a, could predict treat-
ment response in newly diagnosed GBM pati s.
Materials and methods
Patient population
This study was conducted in the VUmc and was regis ed by the 
Medical Ethical Committee (2004/139). Each patient provi ed 
written informed consent. Included patients with histologically 
confirmed newly diagnosed glioblastoma received standard 
first-line treatment [surgery followed by irradiation (total of 
60 Gy), with concomitant temozolomid  (75 mg/m2) and adju-
vant six cycles of temozolomide, dosed 150–200 mg/m2, 5 days 
per week in cycles of 4 weeks]. Serum samples were collected 
at three different time points: pos operative, after chemoradia-
tion, and after completion of the adjuvant treatment phase.
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was present with a Pearson’s correlation coefficient of 0.78 
(p < 0.001) (Fig. 1c). To view distribution of the treatment 
response a histogram was generated from PFS and a Gauss-
ian distribution was fitted. The goodness of fit and 95 % 
(version5). Concentrations of candidate protein biomark-
ers were determined after log-transformation of absorbance 
values. Data was imported in SPSS (version20). Log trans-
formation was applied to reach normal distributions. Pear-
son’s correlation coefficient was determined to assess linear 
relationship between parameters. Serum peptide spectra 
were analyzed using our OPL-Analyzer software package as 
described before [14]. The data was pre-analyzed by prepara-
tion of metadata and the processing of raw mass spectrom-
etry signals, which consists of peak detection, alignment, 
normalization and deisotoping. The peptides were further 
subjected to intensity filtering, requiring the median inten-
sity of at least one group to be greater than 80 units and the 
fold change of the median intensities of two groups greater 
than 1.5. Candidate peaks were examined visually by spec-
tra overlay in Matlab and subjected to principle component 
analysis (PCA), unsupervised cluster analysis and univariate 
Cox regressions. All these analysis were performed without 
assignment of response group labels. Predictive signatures 
were generated by support vector machine (SVM), random 
forests (RF) and k-nearest neighbor statistical models, using 
peptide profiles from 24 randomly selected patients as train-
ing set. Performance of the predictive signatures was tested in 
the 26 remaining patients as independent test-set. Multivari-
ate Cox regressions and subgroup analysis were performed to 
compare short versus long responders as determined by PFS. 
To view distribution of the treatment response a histogram 
was generated from PFS and a Gaussian distribution was fit-
ted. The goodness of fit and 95 % confidence intervals will be 
assessed in Graphpad prism. For the subgroup analysis the 
two tailed unpaired Student’s t test was used. All p values 
smaller than 0.05 were considered statistically significant.
Results
Patient cohort and treatment response
Between 2005 and 2012, 55 patients, were included. Table 1 
summarizes the patient characteristics.
Two of the 55 patients were treated differently, with 
chemoradiation at a dose of 42 Gy, without adjuvant temo-
zolomide. The mean number of cycles completed in the 
adjuvant phase was five (range 1–6). In 12 patients, dose 
reductions with temozolomide were needed in the adjuvant 
phase, because of toxicity CTC grade 3 and 4.
Follow-up of treatment response (PFS) was censored on 
November 8th 2012 in nine patients. Survival was censored 
in 18 out of 55 patients. Median PFS was 10 months (range 
2–52 months) (Fig. 1a). Median OS was 15 months (rang  
3–52 months), and 2 year survival was 25 % (Fig. 1b).
Correlation between PFS as determined by the Macdon-
ald response criteria and OS was mea ured. A correlation 
Table 1 Patient character stics









Female 12 (31) 4 (25)
Male 27 (69) 12 (75)
Histology—no (%)
Glioblastoma 39 (100) 16 (100)
Tumor location—no (%)
Left 14 (36) 5 (31)
Right 20 (51) 11 (69)
Multifocal 5 (13) –
WHO performance
0 22 (56 %) 8 (50 %)
1 15 (38 %) 6 (38 %)
2 1 (3 %)
Missing 1 (3 %) 2 (13 %)
Extent of surgery
B opsy 4 (10 %) –
Debulking
Partial 15 (38 %) 10 (63 %)
Maximal 9 (23 %) 6 (38 %)
Unknown 11 (28 %)




42 Gy 2 (5 %)
75 Gy 37 (95 %) 16 (100 %)
TMZ—dose
0 mg/m2 2 (5 %) –
75 mg/m2 37 (95 %) 16 (100 %)
Dose reductions (number of pat)4 (10 %) 2 (13 %)
Average adjuvant cycles—no4.2 5
Corticosteroid therapy
Yes 19 (49 %)** 1 (6 %)**
No 20 (51 %)**15 (94 %)**
Anti-epileptic therapy
Yes 18 (46 %) 9 (56 %)
No 20 (51 %) 7 (44 %)
Missing 1 (3 %) –
*p = 0.02 and **p =  0.002
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PFS (p =  0.010), and between use of corticosteroids and 
PFS (p < 0.001) were found. No correlations were found 
between treatment response (PFS) and extent of resection, 
WHO performance score, gender, tumor location, or use of 
anti-epileptic drugs (Table 1). We reasoned that it would 
be clinically useful to identify the patients that will have 
long standing responses. Patients with PFS longer than 
16 months (2× tandard deviation of the mean) have sub-
stantial benefit of treatment and were therefore classified 
as the favorable response group and as long responders. 
We compared significantly associated factors in the short 
(<16 months) versus long (>16 months) responders. Both 
age and corticosteroids use were significantly different 
confidence intervals were assessed in Graphpad prism. The 
observed responses fitted well with a Gaussian distribution 
model with a R2 of 0.86 and narrow confidence interval for 
the mean (6.6–9.4 months). Mean of the Gaussian distribu-
tion was 8.0 months with a standard deviation of 4.9 months 
(95 % confidence interval 3.5–6.3 months) (Fig. 1d).
Correlation between patient characteristics and 
treatment outcome
By using univariate Cox regression analysis, signifi-
cant correlations between age at the time f surgery a  
PFS (p =  0.008) between postoperative tumor r sidue nd 
Fig. 1 a Outcome of first-line treatment in patients with glioblastoma. 
Treatment response of patients with glioblastoma that received radio-
therapy and concomitant and adjuvant temozolomide. Kaplan–Meier 
curves show that (a) median PFS is 10 months (range 2–52 months). 
b Outcome of first-line treatment in patients with glioblastoma. Treat-
ment response of patients with glioblastoma that received radiotherapy 
and concomitant and adjuvant temozolomide Kaplan–Meier curves 
show that (b) median OS is 15 onths (range 3–52 months). c Correla-
tion between PFS and OS by P arson correlation. Correlation between 
PFS and OS of patients with glioblastoma who received radiotherapy 
and concomitant and adjuvant temozolomide was assessed by Pear-
son correlation. d Normal distribution. General response (PFS) tends 
to follow a normal distribution with a distinct group of patients that 
responds beyond 16 months
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the first sample taken was 21 days, the mean time was 
23 days (range 13–33 days).
All serum samples were measured by MALDI-TOF 
mass spectrometry. After initial quality control and pre-
processing of the mass spectrometry chromatograms, in 
total 274 peptide peaks were detected above the signal 
intensity threshold. Principal component analysis and 
unsupervised cluster analysis were performed to look at 
variation between samples. Both analyses showed three 
serum samples clustering separately from all other samples. 
These three serum samples were hemolytic before mea-
surements and spectra were of poor quality and were there-
fore excluded from further analyses. We performed another 
unsupervised cluster analysis and labeled samples by gen-
der and poor (<16 m nths) versus favorable (>16 months) 
treatment response (Fig. 3a). No grouping was observed 
by either gender or treatment response. Univariate Cox 
regression analysis was performed to investigate correla-
tion between peptide levels and treatment response (PFS). 
In total 36 peptide peaks showed significant correlation 
with PFS. Visual inspection of the 36 raw peptide spectra 
was done and revealed 14 peaks of sufficient quality for 
between the two response group , while calculated post-
operative tumor residue was not significantly different 
between the two response groups (p =  0.30). Multi-variate 
Cox regression analysis showed that both increasing age 
(HR 1.03, 95 % CI 1.01–1.06), postoperative tumor resi-
due (HR 1.07, 95 % 1.02–1.15), and cortic steroid use (HR 
3.26, 95 % CI 1.67–6.39) before start of chemoradiation 
(i.e. postoperatively) are i de ndently as ociated with 
unfavorable treatment outcome. It s evident that only c r-
ticosteroid use before start of che oradiation was strongly 
predictive for outcome. We found a significantly differ-
ence between mean PFS and OS of 7.3 and 14.6 months 
in patients using corticoste oids before start of chemora-
diation, versus 16.1 and 21.6 months in patient  not using 
corticosteroids before start of chem adiation (p =  0.0005 
and p = 0.0067, respectively) (Fig. 2a, b).
No correlation between postope ative serum peptide 
profile and treatment response
From 50 patients, serum was collected before start of 
chemoradiation. The median tim  between operation and 
Fig. 2 a PFS in the group of patients using corticosteroids before start 
of chemoradiation versus the group of patients not using corticoste-
roids before start of chemoradiation. A significantly difference has 
been found between mean PFS of 7.3 months in patients using cortico-
steroids before start of chemoradiation versus 16.1 months in patients 
not using corticosteroids before start of chemoradiation (p =  0.0005). b 
OS  the group of patients using corticosteroids before start of chemo-
radiation v rsus the group f patients not using corticosteroids before 
start of chemoradiation. A significantly difference has been found 
be ween me n a d OS of 14.6 months in patients using corticosteroids 
before start of che radiation versu  21.6 months in patients not using 
corticosteroids before start of chemoradiation (p =  0.0067)
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Candidate protein biomarkers in serum samples
From 47 patients, enough serum was available for measure-
ments of haptoglobin, YKL-40, Fetuin-A and thrombocytes, 
after initial serum peptide profiling. Median haptoglobin 
concentration was 1.9 g/L (range 0.5–4.6 g/L), median 
thrombocyte count was 288 × 109 cells/L (range 158–
529 ×109 cells/L). Haptoglobin concentration was above 
the reference level in 18 patients (38 %), while thrombocy-
tosis was present in 7 patients (13 %). A significant decrease 
of haptoglobin concentrations was present after complet-
ing the adjuvant phase, but not after completing chemora-
diation (p <  0.0001, Suppl.Fig.S1). No significant change in 
thrombocyte counts was found (Suppl.Fig.S2). Similarly, 
follow-up. After correction of p-v lues for multiple te t-
ing, none of the peptide peaks was significantly different 
between the two groups.
Despite these results in univariate nalysis, we argued that 
combination of multiple peptides tog her may stil  yield pre-
dictive power. Therefore, we used hree different statistical 
models to generate the best performing predi tive signatures 
in a subset of 18 patients. Using support vec r machine, a 
24-peptide signature was develop d for r sponse pr dic o . 
Still, the performance of the igna ure in the indep ndent test-
set was insufficient to separate responding from unresponsive 
patients (p =  0.42) (Fig. 3a). Similar results wer obtained
with different training strateg es s ch as k-nearest ne ghb ur 
(p =  0.24) and random forests (p =  0.44) (Fig. 3b–d).
Fig. 3 a Categorization in a short versus long treatment response 
group based on serum peptide profiling. Serum was collected post-
operatively, before start of chemoradiation and peptides were profiled 
by MALDI-TOF-MS. Unsupervised cluster analysis was performed 
and samples were labeled by gender and good (PFS >16 months) ver-
sus poor treatment response (PFS <16 months). b–d Result of testing 
potential predictive classifiers to predict treatment esponse. Predic-
tive classifiers were generated from the peptide profiles of 18 patients. 
Each classifier was tested in an independent patient set of 26 patients. 
Signatures generated by support vector machine (a), k-nearest neigh-
bor (b) and random forrest (c) did not predict treatment response (b–d)
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collected after surgery cannot predict outcome of multimo-
dality treatment. This may be due to the fact that GBM is a 
heterogeneous disease with different molecular abnormali-
ties that may preclude the ability to identify a single set of 
proteins that reflects outcome. The total number of pep-
tides identified in this analysis was comparable to the total 
number of identified peptides in a previous study from our 
department [14]. They found that serum peptidome profiling 
may aid in prediction of treatment outcome of patients with 
advanced non-small cell lung cancer (NSCLC) treated with 
chemotherapy [14]. Furthermore, the clinical predictive 
potential of peptide profiling for systemic treatment was 
shown by Gregorc et al. They found a predictive proteomic 
signature in patients with NSCLC treated with second-line 
erlotinib or chemotherapy [26] and supported by multiple 
studies evaluating MS-based serum and plasma peptidome 
profiling for prediction of treatment outcome in patients 
with solid malignancies as summarized previously [27]. 
Our inability to find a predictive peptide profile for GBM 
patients may indicate that pre-operative serum might be a 
more suitable source for this analysis. However, even after 
optimal resection of a GBM, (microscopic) tumor residue 
is being left. In addition, patients with advanced NSCLC 
in the study of Voortman and colleagues were treated with 
chemotherapy only, and they did not receive any surgery 
[14]. Others reported that serum peptide profiles can also be 
used as a sensitive measure for early prediction of disease 
relapse after surgery [28, 29]. In this study, we observed no 
significant distinction between patients with maximal ver-
sus subtotal resection in unsupervised cluster analysis [data 
not shown], suggesting that peptide profiles may have less 
potential in GBM patients.
Serum YKL-40 concentration has been suggested as a 
useful biomarker for monitoring disease relapse in GBM 
patients [30, 31]. YKL-40 was shown to be overexpressed 
in tumor tissue of patients, enhancing tumor growth and 
angiogenesis [34]. We found very little variation in YKL-40 
protein concentrations in serum of patients throughout the 
disease course. This is a remarkable finding, since others even 
reported a transient decrease of protein levels postoperatively, 
while using the same bioassay [31]. We did not observe any 
correlation between extent of resection and serum YKL-40 
that was previously reported in GBM patients [35]. We also 
found no correlation at different time points between post-
operative tumor volume and serum YKL-40 concentrations.
In contrast to YKL-40, Fetuin-A and haptoglobin are pro-
teins that are also abundantly present in serum of healthy 
individuals. Fetuin-A was found to be increased, while hap-
toglobin was demonstrated to be decreased in GBM patients 
with favorable prognosis [9, 10]. We ob erved a similar 
trend without significance for both molecules in our regres-
sion analysis. Significant changes in biomarker concentra-
tions were detected when comparing pre-chemoradiation 
no significant correlation was found between haptoglobin 
concentrations (p =  0.16) or thrombocyte counts and PFS. 
Median YKL-40 and Fetuin-A concentrations were 37.8 ng/
mL (range 21.8–183.3 ng/mL) and 460.9 mg/L (range 
236.4–901.4 mg/L) respectively. B th YKL-40 and Fetuin-
A concentrations were significantly increased, when com-
paring the pre-chemoradiation samples w th the samples 
after chemoradiation (p =  0.0002, p =  0.0026, suppl.Fig.S3, 
S4). Both YKL-40 and Fetuin-A concentrat ons were n t
associated with PFS as determined by Cox regression analy-
sis (p =  0.54 and p =  0.25 respectively). How ver, when com-
paring concentrations in our previously identified response 
groups, Fetuin-A was significantly increased in patients 
with favorable treatment re po se (p=  0.03) (Fig. 4a–d).
Discussion
We performed a population-based study of 55 patients with 
a newly diagnosed glioblastoma, who were treated with cu-
rent standard treatment. In comparison to the initial registra-
tion trial, our patient coh r  is a presentative cohort with 
an OS of 14.6 months and a PFS wa 10 months [1]. The 
response to chemoradiation usually tends to follow  norma  
distribution, while in this patient cohort a distinct subgroup 
existed that responded longer t an 16 m ths and surviv d 
the first 2 years. Similar to other studies, we found younger 
age, no corticosteroid treatment befor  sta t of chemoradia-
tion and low postoperative tumor volume impor ant predic-
tive factors for a favorable treatment response and s rvival 
[3, 19]. In contrast to some other studi s, perfo mance status 
and extent of surgical resectio  did not predict for treatment 
outcome.
In general, but for brain t mors in particular, bl od rep-
resents an attractive platform for prediction and monitoring 
of treatment response since it is easy to obtain by venous 
puncture. In previous studies peptide profiles in serum of 
patients with glioblastoma differed from healthy donors 
[10, 20]. Gollapalli and colleagues compared the serum 
proteome of patients with GBM and healthy subjects and 
revealed 55 differentially expressed and statistically signifi-
cant (p < 0.05) protein spots [20]. Several studi s d mon-
strated that serum peptide profiles can be used for diagnostic 
purposes and early detection of cancer [21, 22]. Th s indi-
cates that peptide profiles represents a sensitive tool, which 
may be useful to guide therapeutic decisions in daily prac-
tice. Moreover, the serum pept dome was shown to harbor 
robust biomarkers for pred ct on of trea me t resp nse, 
including chemoradiation, in other types of cancer [23, 24]. 
We collected serum from GBM patients p stop rative, aft r
chemoradiation, and after completion of he whole treat-
ment. Analysis of the serum peptide profiles did not yield a 
predictive signature, so we concluded that peptides in serum 
1 3
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pre-treatment samples when comparing the poor and good 
response groups, suggesting that the power of our analysis 
may have been insufficient.
samples with samples taken afte  completing whole treat-
ment, indicating that timing of sampling may be of impor-
tance. Interestingly, Fetuin-A was significantly increased in 
Fig. 4 Analysis of candidate biomarkers and correlation of candi-
date biomarkers with treatment response. Protein concentrations of 
previously published candidate biomarkers were measured in serum 
samples by ELISA (a, d) or immunonefolometry. b Thrombocyte 
counts were measured by a CD4000 impedance hematology analyzer. 
c Correlation with treatment response was determined by Cox regres-
sion (not sh wn) and group comparison. Fetuin-a protein concentra-
tions were significantly different between good and poor respon e 
groups (p =  0.03)
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G, Gonzalez-Aguilar A et al (2012) Response assessment in 
recurrent glioblastoma treated with irinotecan-bevacizumab: 
Although these biomarkers could still be of value, cor-
relations may be too weak for robust prediction of treatment 
response. Even, grouping these individu l biomarkers in 
high and low levels did not provide any predictive value 
(data not shown). All currently es ablished predictive bio-
markers are derived from tumor tissue. The advent of large 
scale genomic profiling allows comprehensive studies of the 
driver molecules in glioblastoma. For example PDGFR and
EGFR were identified as important molecules, together with 
p53, RB1 and NF1 [36]. Molecular alterations however may 
change over time, particularly when treatment is involved, 
urging repeated surgical interventions. The methylation of 
the MGMT-gene promotor and IDH1 utations as prog-
nostic and/or predictive factors were not evaluated in our 
study due to its retrospective natur . Most p bably heir 
potential value will not change our inability to find a reliable 
prognostic or predictive circulating biomarker in serum for 
patients with GBM.
Still, the non-invasive platforms in blood that are cur-
rently in development may bec me par  of futur  patient 
management. Circulating tumor cells or extracellular vesi-
cles are shed by tumors into the circulation and may harbor 
tumor specific molecules [37]. Epigenetic featur s uch as 
MGMT promoter methylation stat s are strong predictors 
of treatment response and may be ass ssed in serum [38]. 
In addition, we previously found that platelet contents may 
provide a biomarker for disease nd treatment response 
evaluations [39]. We have demonstrated that tumor cells 
transfer (mutant) RNA into blood pla elets in vi ro and in 
vivo, and showed that blood platelets isolated from glioma 
and prostate cancer patients cont in the cancer-associated 
RNA biomarkers EGFRvIII and PCA3, respectively. In 
addition, gene-expression profiling revealed a distinct RNA 
signature in platelets from glioma patients compared with 
normal control subjects [39]. Therefore we are currently 
sampling platelets from patients with a GBM that undergo 
first-line treatment. These tools can help monitoring drug 
resistance, guide therapeutic decisions to improve outcome 
for patients with GBM.
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